Veradermics (MANE) Stock Price, Quote, News & History | Benzinga

SPY777.39−0.22%QQQ757.06−0.34%BTC/USD83,110.10−2.85%DIA511.60−0.58%GLD377.18−1.33%TLT77.17−0.15%

Veradermics Inc (MANE) Stock Price, Quote, News & History

MANENYSE

Trade with Public

Trade with Public

$109.50

0.540.5%

Last update: Oct 7, 6:49 AM

$109.50

0.540.5%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$109.00

Close

-

Volume / Avg.

357.29K / 717.70K

Day Range

$108.84 - $113.43

52 Wk Range

32.00 - 131.24

Market Cap

$4.57B

P/E Ratio

-

Dividend Yield

-

Exchange

NYSE

RSI

50

Short Interest

15.09%

Days to Cover

7.48

Recent Veradermics, Incorporated News

Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months

Veradermics reported positive phase 2 data for VDPHL01, showing hair growth and favorable safety in women with pattern hair loss.

Vandana Singh

PayPal, Veradermics, Alibaba And Other Big Stocks Moving Higher On Wednesday

US stocks close higher, Dow Jones up 100 points, PayPal shares rise on $53 billion acquisition proposal, other big gains from Aehr Test, Electrovaya, Robo.ai, Falcon's Beyond, Veradermics, Lucid Group, Kopin, MINISO, Mesoblast, Nexstar, Lionsgate, Karman.

Avi Kapoor

This Oppenheimer Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Wall Street analysts changed outlook on top names: ODTX, MOBI, MANE. See analyst ratings page for all changes. MOBI target prices: $16, $19, $31

Avi Kapoor

Crude Oil Gains Over 1%; Verizon Posts Upbeat Earnings

U.S. stocks trade lower on Monday, with Dow falling 0.1%. Verizon beats Q1 earnings, raises FY26 guidance. European shares mixed, Asian markets close mixed.

Avi Kapoor

Newly Listed Veradermics Hair Loss Drug Shows Hair Growth Gains

Veradermics reports Phase 2/3 data for VDPHL01, showing significant hair growth and a safety profile, with shares rising on Monday.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-78.30M

Investing Cash Flow (TTM)

-473.36M

Financing Cash Flow (TTM)

862.40M

Free Cash Flow (TTM)

-78.33M

Capital Expenditure (TTM)

-26.00K

Net Change in Cash (TTM)

310.74M

Analyst Trends and Forecast

1

Apr

1

May

2

Jun

4

Jul

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$3.73B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

5.60

Earnings Yield % (TTM)

-2.29%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$19.47

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$319.33M

Debt to Equity

0.00

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-